Can anyone receive a prescription for oral therapeutic drugs (lagebrio capsule, Pakylovid Pack, Zocova Tablet) if I get infected with COVID-19?

Last update date August 9, 2023

Currently, three of therapeutic agents for mildly ill patients have been approved as oral drugs for mildly ill.

Lagebrio capsule (active ingredient: mornupyravir)
Pakylovid pack (active ingredient: nilumatralvir/litonavir)
Zocova Tablet (active ingredient: nilumatralvifumalic acid)

Each oral drug has the following characteristics, and if it is infected with the new coronavirus, it is not something that anyone needs to receive it.
Follow the doctor's diagnosis for the need for administration.

（１） Lagebrio capsule

Characteristics
Subject to administration	Those who are at risk of serious illness, such as elderly people, obesity, and those with underlying diseases
Those who can not administer	Pregnant women or women who may be pregnant
Deadline to start taking	Within 5 days of onset

（２） Pakilobid pack

Characteristics
Subject to administration	Those who are at risk of serious illness, such as elderly people, obesity, and those with underlying diseases
Precautions for taking	Multiple agents cannot be used in combination
Deadline to start taking	Within 5 days of onset

（３） Zocova Tablet

Characteristics
Subject to administration	Those who are not at risk of severe illness and have clinical symptoms such as high fever, strong cough symptoms, and strong sore throat
Those who can not administer	Pregnant women or women who may be pregnant
Precautions for taking	Multiple agents cannot be used in combination
Deadline to start taking	Within 3 days of onset

For inquiries to this page

Health and Safety Division, Medical Care Bureau Health and Safety Department

Phone: 045-671-2463

Fax: 045-664-7296

Email address: ir-kenkoanzen@city.yokohama.jp

List of related pages Open the menu in the related page list

Return to the previous page

Page ID: 628-531-304